Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DUZALLO | Ironwood Pharmaceuticals | N-209203 DISCN | 2017-08-18 | 2 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
allopurinol | ANDA | 2025-03-05 |
allopurinol sodium | ANDA | 2022-03-01 |
aloprim | New Drug Application | 2022-02-18 |
zyloprim | ANDA | 2018-02-24 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
gout | EFO_0004274 | D006073 | M10 |
hyperuricemia | — | D033461 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | — | 1 |
Gout | D006073 | EFO_0004274 | M10 | — | — | — | 1 | — | 1 |
Drug common name | Allopurinol |
INN | allopurinol |
Description | Allopurinol is a bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. It has a role as a radical scavenger, a gout suppressant, an antimetabolite and an EC 1.17.3.2 (xanthine oxidase) inhibitor. It is an organic heterobicyclic compound and a nucleobase analogue. It derives from a hydride of a 1H-pyrazolo[4,3-d]pyrimidine. ... More |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Oc1ncnc2[nH]ncc12 |
PDB | — |
CAS-ID | 315-30-0 |
RxCUI | — |
ChEMBL ID | CHEMBL1467 |
ChEBI ID | 40279 |
PubChem CID | 135401907 |
DrugBank | DB00437 |
UNII ID | 63CZ7GJN5I (ChemIDplus, GSRS) |